In this context,ruxolitinib, the first topical JAK inhibitor approved for AD, servesas a clinically validated example of the benefits of the topical approach. Furthermore, topical soft drugs that are activein the skin with minimal systemic exposure due to the presence ofsoft spots targeting JAKs have been developed, such as CEE321. In the pursuitof novel topical agents for AD, the group led by Zhongjian Chen exploredthe therapeutic potential of JAPT7 and JAPT8, two PROTACs targeting JAK1 and JAK2 previously developed for thetreatment of lymphoblastic leukemia. This evidence concerns the gene JAK1 and Alzheimer disease.